Insider buying last 90 days
No open-market insider purchases were filed for RDY in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Dr. Reddy's Laboratories (RDY) draws attention this week after Brazil's ANVISA granted marketing authorization for the company's once-weekly generic semaglutide injection, a regulatory clearance tied to its diabetes portfolio. Separately, CEO Erez Israeli proposed selling 460,726 sponsored ADRs acquired through stock options, alongside an employee allotment of 591,270 shares under the company's ADR stock option scheme. Shares also saw a session where they underperformed the broader Indian market, closing below their 52-week high.
RDY closed at $15.05, up 0.9%, sitting above both its 50-day average of $12.83 and 200-day average of $13.25, with one-month returns of 20.6% and three-month returns of 20.9%. The GekkoIndex reads 42.3, placing the stock in the Distribution zone. Price stands 6.3% above the Gekko Fair Value of $14.16.
The next earnings date falls on 22 January 2027, outside a typical 20-trading-day window, with the last report showing EPS of $0.06 against an estimate of $0.17 and a -9.2% reaction. No insider, Congress, or unusual options activity appears in the respective 90-day and 30-day windows. Seasonality over the next 20 trading days has averaged -1.5% across 5 years, rising in 2 of them. Analyst consensus from 3 firms shows 2 buy and 1 hold ratings, with a consensus target of $14.47.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Dr. Reddy's Laboratories scores 1 supportive, 3 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
1 supportive3 mixed1 headwind
Averages disagree
Close $14.74 sits between the 50-day ($13.04) and 200-day ($13.28) averages, or the averages disagree.
See the chart48, Neutral
Reading 48 is in the Neutral zone.
See the GekkoIndex7.9% above
Price is 7.9% above Gekko Fair Value (more than 5% above).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 68 days
Next report Jan 22, 2027, 68 days away — outside a typical 20-trading-day hold.
See earnings−0.7% on average
From this point in the calendar, the next 20 trading days averaged −0.7% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Dr. Reddy's Laboratories closed at $14.74 on Nov 13, 2026, +6.4% over the past year, inside a 52-week range of $11.36 to $15.67.
Use the left and right arrow keys to read daily values.
Put RDY on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Dr. Reddy's Laboratories operates as a full-scale pharmaceutical business with reach across many countries. It makes and sells both branded and generic medicines, covering areas such as digestive health, heart conditions, diabetes, skin treatments, cancer, breathing disorders, dental care, and kidney and urinary conditions. Its generic drugs are built to match the therapeutic effect of their branded counterparts, and this side of the business also includes biologic products.
Beyond finished medicines, the company produces active pharmaceutical ingredients and related chemical components used as inputs for drug manufacturing, along with contract research work and custom-made ingredients and steroids for outside clients. It also has a unit focused on developing new proprietary drug formulations, and another working on treatments for cancer and inflammatory diseases. A collaboration with Curis, Inc. supports work on small molecule compounds aimed at immuno-oncology and precision oncology.
Dr. Reddy's was established in 1984 and is headquartered in Hyderabad, India. Its shares trade under the ticker RDY.
Dr. Reddy's Laboratories’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 48, in the Neutral zone, up 5.8 points over five sessions.
Up 5.8 points over five sessions, from the Distribution zone.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 37 | +1.9% | +4.1% | ||
| Accumulation | 266 | +0.1% | +0.1% | ||
| Neutral (current zone) | 325 | −0.2% | −0.2% | ||
| Distribution | 25 | +0.6% | −3.0% | ||
| Selling | 2 | Too few readings yet | |||
Average RDY share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Dr. Reddy's Laboratories trades 7.9% above Gekko Fair Value of $13.66, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Dr. Reddy's Laboratories shares are worth, recalculated every trading day.
$13.66
Gekko Fair Value, Nov 14, 2026
7.9% Overvalued
At the end of Aug 2026 the price was 13.0% below the estimate.
No open-market insider purchases were filed for Dr. Reddy's Laboratories, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for RDY in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in RDY were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Dr. Reddy's Laboratories reports on Jan 22, 2027, before the open (68 days away), and beat the EPS estimate in 4 of its last 8 reports.
Jan 22, 2027
Expected before the open, 68 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 21, 2026 | $0.06 est $0.17 | $835.7M est $850.6M | −9.2% |
| May 11, 2026 | $0.00 est $0.16 | $785.9M est $886.6M | −5.8% |
| Jan 20, 2026 | $0.16 est $0.16 | $951.6M est $927.7M | +2.8% |
| Oct 24, 2025 | $0.20 est $18.31 | $1.00B est $979.8M | −1.0% |
| Jul 23, 2025 | $17.02 est $0.21 | $988.9M est $1.01B | +2.1% |
| May 9, 2025 | $19.11 est $17.13 | $996.2M est $978.2M | +5.7% |
| Jan 29, 2025 | $16.94 est $16.15 | $969.6M est $975.7M | +2.1% |
| Nov 5, 2024 | $15.83 est $17.69 | — | +2.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Dr. Reddy's Laboratories is $14.41, −2.2% from the last close, from 3 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 3 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 26 | Bank of America Securities | — | — |
| Oct 25 | Jefferies | $13.86 | −6.0% |
| Oct 12 | Exane BNP Paribas | $14.80 | +0.4% |
| Oct 1 | Bank of America Securities | — | — |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Dr. Reddy's Laboratories averaged −0.7% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.0% | 1 of 5 |
| Next 10 trading days | −0.3% | 2 of 5 |
| Next 15 trading days | −0.9% | 1 of 5 |
| Next 20 trading days | −0.7% | 3 of 5 |
| Next 30 trading days | +2.0% | 3 of 5 |
For scale, RDY’s typical 20-trading-day move in either direction is about 4.3%.
Dr. Reddy's Laboratories’s market cap is $12.29B, with a P/E ratio of 41 and revenue of $329.8B over the last twelve months.
2 headlines about Dr. Reddy's Laboratories from the past week, newest first, each linking to the publisher.
Dr. Reddy's Laboratories’s market cap is $12.29B at the Nov 13, 2026 close of $14.74, with 833.7M shares outstanding. The shares trade on a P/E ratio of 41.
The consensus analyst 12-month price target for Dr. Reddy's Laboratories is $14.41, −2.2% from the last close. Of the 3 firms that rated the stock in the last 90 days, 2 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Dr. Reddy's Laboratories is overvalued: the Nov 13, 2026 close of $14.74 is 7.9% above Gekko Fair Value of $13.66. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Dr. Reddy's Laboratories is expected to report on Jan 22, 2027, before the market opens (68 days away). Analysts expect earnings of $0.15 per share on revenue of $952.7M. Dr. Reddy's Laboratories beat the earnings estimate in 4 of its last 8 reports, moving 3.9% on average across the report.
Dr. Reddy's Laboratories’s 52-week high is $15.67 and its 52-week low is $11.36; it closed at $14.74 on Nov 13, 2026, +6.4% over the past year. Over the last five years the shares peaked at $16.89 on Aug 9, 2024.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 1 of the 5 items with data read as supportive (earnings risk), 3 as mixed (trend, gekkoindex and seasonality) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.